Aztreonam for Inhalation

Elliott, William T.; Chan, James
April 2010
Internal Medicine Alert;4/29/2010, Vol. 32 Issue 8, p62
The article offers information on the new monobactam antibacterial Aztreonam inhalation which has received an approval from the U.S. Food and Drug Administration (FDA), was formulated for the treatment of cystic fibrosis (CF) patients who are infected with Pseudomonas aeruginosa and other gram-negative bacteria and was marketed as Cayston® by Gilead Sciences Inc. which can be administered using the Altera® Nebulizer System.


Related Articles

  • FDA recommends aztreonam for treatment of P. aeruginosa in patients with cystic fibrosis.  // Infectious Diseases in Children;Mar2010, Vol. 23 Issue 3, p48 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) Anti-Infective Drug Advisory Committee to recommend the efficacy and safety of a formulation of aztreonam.

  • In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. Yu, Qianru; Griffin, Edward F.; Moreau-Marquis, Sophie; Schwartzman, Joseph D.; Stanton, Bruce A.; O'Toole, George A. // Journal of Antimicrobial Chemotherapy (JAC);Nov2012, Vol. 67 Issue 11, p2673 

    Objectives Aztreonam for inhalation solution (AZLI) was recently approved by the FDA for treating cystic fibrosis (CF) patients infected with Pseudomonas aeruginosa. Here we investigated the effect of aztreonam alone or in combination with tobramycin on P. aeruginosa biofilms grown on CF airway...

  • Public health: The politics of antibiotics. Cully, Megan // Nature;5/1/2014 Supplement, Vol. 509 Issue 7498, pS16 

    The article focuses on the overuse of antibiotics in agriculture and medicine and efforts being done by the U.S. governments and social organizations to reduce the issue. Topics discussed include uses of antibiotics in livestock in treating active bacterial infections, guidelines from the U.S....

  • Bad bugs need more drugs. Opar, Alisa // Nature Reviews Drug Discovery;Dec2007, Vol. 6 Issue 12, p943 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to issue the first of its long-awaited guidelines for clinical trials of drugs to treat bacterial infections. It states that prompted by the Infectious Diseases Society of America (IDSA), the requirement to issue...

  • Unmet Needs and Prospects for Oritavancin in the Management of Vancomycin-Resistant Enterococcal Infections. Arias, Cesar A.; Mendes, Rodrigo E.; Stilwell, Matthew G.; Jones, Ronald N.; Murray, Barbara E. // Clinical Infectious Diseases;2012 Supplement 3, Vol. 54, pS233 

    The treatment of infections caused by vancomycin-resistant enterococci (VRE) has become an important clinical challenge and compromises the care of critically ill patients. A striking increase in the frequency of nosocomial isolation of multidrug-resistant Enterococcus faecium has dramatically...

  • Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Pathak, Rahul; Enuh, Hill Ambrose; Patel, Anish; Wickremesinghe, Prasanna // Clinical & Experimental Gastroenterology;2014, Vol. 7, p1 

    Background: Clostridium difficile infection (CDI) has become a global concern over the last decade. In the United States, CDI escalated in incidence from 1996 to 2005 from 31 to 64/100,000. In 2010, there were 500,000 cases of CDI with an estimated mortality up to 20,000 cases a year. The...

  • Pressure on US FDA to add black box warning to fluoroquinolones.  // Reactions Weekly;9/9/2006, Issue 1118, p2 

    The article reports that the Public Citizen has petitioned the U.S. Food and Drug Administration to add a black box warning that highlights the risk of tendinotpathy and tendon rupture to the labelling of all fluoroquinolone antibacterials. According to the Public Citizen, there are 262 cases of...

  • Recent FDA Drug Approval: Aztreonam.  // Clinical Pediatrics;Oct1987, Vol. 26 Issue 10, p504 

    This article reports that aztreonam for injection has been approved by the U.S. Food and Drug Administration for the treatment of certain infections caused by susceptible gram-negative micro-organisms and for adjunctive therapy to surgery in the management of infections caused by susceptible...

  • Despite Concerns, Panel Backs Gilead Inhaled Aztreonam in CF. Young, Donna // BioWorld Today;12/11/2009, Vol. 20 Issue 238, p1 

    This article reports on the U.S. Food and Drug Administration (FDA) support received by Gilead Sciences Inc.'s aerosolized form of aztreonam lysine as a therapy to improve respiratory symptoms and pulmonary function in cystic fibrosis patients infected with Pseudomonas aeruginosa. The agency's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics